Warning letter
Natco Pharma Limited: warning letter of Apr 8, 2024
FDA warning letter 672564 · Center for Drug Evaluation and Research | CDER
Key facts
| Reference number | 672564 |
|---|---|
| Company | Natco Pharma Limited |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Apr 8, 2024 |
| Posted date | Apr 16, 2024 |
| Issuing office | Center for Drug Evaluation and Research | CDER |
| Product type | Drugs |
| CFR sections cited | 211.67(a), 211.192 |
| Inspection city | Rangareddy |
| Inspection start date | Oct 9, 2023 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: